Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Mar 2020 Results summarizing malignancy rates in psoriasis clinical studies of brodalumab (NCT00975637; NCT01101100; NCT01708590 (AMAGINE-1); NCT01708603 (AMAGINE-2); NCT01708629 (AMAGINE-3).) published in the American Journal of Clinical Dermatology
05 Jun 2019 Results published in the Journal of the American Academy of Dermatology
03 Oct 2017 Results (n=4464) of exploratory analysis assessing psychiatric adverse events occurrence across late stage brodalumab patients using patient data from NCT00975637, NCT01101100, NCT01708590, NCT01708603 and NCT01708629 trials and their open label extensions published in the Journal of the American Academy of Dermatology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com